| Rank |
Status |
Study |
| 1 |
Recruiting
|
Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery
| Conditions: |
Post-operative Nausea; Post-operative Vomiting; Post-discharge Nausea; Post-discharge Vomiting |
| Intervention: |
Other: Anesthesia and postoperative medication and fluid protocol |
| Outcome Measures: |
Post-operative nausea and vomiting; Hospital length of stay; Post-discharge nausea and vomiting |
|
| 2 |
Recruiting
|
Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting
| Conditions: |
Chemotherapy-induced Nausea and Vomiting; Moderate Emetogenic Chemotherapy |
| Intervention: |
|
| Outcome Measures: |
To evaluate the role of some predictive biomarkers for chemotherapy-induced nausea and vomiting; To evaluate the clinical characteristics related to chemotherapy-induced nausea and vomiting in Korean patients |
|
| 3 |
Not yet recruiting
|
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
| Conditions: |
Hematopoietic/Lymphoid Cancer; Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific |
| Interventions: |
Drug: Olanzapine; Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other: Placebo |
| Outcome Measures: |
Proportion of patients with no nausea, defined as a response of 0 in the nausea item of Nausea and Vomiting Daily Diary/Questionnaire; Nausea scores measured by the Nausea and Vomiting Daily Diary/Questionnaire; Complete response, defined as no emetic episodes and no use of rescue medication measured by the Nausea and Vomiting Daily Diary/Questionnaire; Incidence of potential toxicities related to olanzapine as measured by the Nausea and Vomiting Daily Diary/Questionnaire; Frequency of rescue medication repeatedly measured by the Nausea and Vomiting Daily Diary/Questionnaire |
|
| 4 |
Not yet recruiting
|
Inhalation Intervention for Nausea in the Emergency Department
| Conditions: |
Nausea; Vomiting |
| Interventions: |
Other: Alcohol prep pad group; Other: Placebo Normal Saline prep pad |
| Outcome Measures: |
Significant change in level of nausea.; Time to effect for significant change in nausea level |
|
| 5 |
Recruiting
|
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
| Conditions: |
Breast Cancer; Nausea; Vomiting |
| Interventions: |
Drug: granisetron transdermal system; Drug: fosaprepitant dimeglumine; Other: laboratory biomarker analysis |
| Outcome Measures: |
Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment); Proportion of patients with complete response, defined as no emesis and no use of rescue medication in delayed phase (within 2-4 days of treatment); Proportion of patients with complete response, defined as no nausea, defined as Visual Analog Scale (VAS) less than 5 mm on a 0-100mm horizontal scale in acute phase (within 24 hours of treatment); Proportion of patients with complete response, defined as no nausea, defined as VAS less than 5 mm on a 0-100mm horizontal scale in delayed phase (within 2-4 days of treatment); Proportion of patients with partial response, defined as 2 or fewer episodes of emesis (Common Terminology Criteria for Adverse Events [CTCAE] version 4.0 grade 1-2), regardless of the use of rescue antiemetic medications (in acute and delayed phase); Proportion of patients with treatment failures, defined as more than 2 episodes of emesis (CTCAE version 4.0 grade 2 or greater), regardless of the use of rescue antiemetic medications; Proportion of patients with partial response, defined as no significant nausea, defined as VAS less than 25 mm on a 0-100mm horizontal scale (in acute and delayed phase); Proportion of patients who developed nausea and vomiting in the first course of treatment out of all enrolled patients; Proportion of patients who developed grade 1, 2, 3, or 4 nausea and vomiting with all courses of treatment out of all patients who developed nausea and vomiting; Proportion of patients who developed nausea and vomiting on all courses; Proportion of patients who experience grade 1, 2, 3, or 4 adverse events out of all patients who have received study drugs; Proportion of patients who missed 0, 1, or more than 2 doses of scheduled antiemetic medication at home on days 2 to 3, out of all patients |
|
| 6 |
Recruiting
|
Dexamethasone for the Prevention of Post-operative Nausea and Vomiting in Patients Undergoing Cesarean Sections
| Condition: |
Postoperative Nausea and Vomiting |
| Interventions: |
Drug: Dexamethasone; Drug: Placebo |
| Outcome Measures: |
Incidence of post-operative nausea and/or vomiting; Total consumption of anti-emetic medications; Subject's self-reported visual analog scale (VAS) pain scores; Overall satisfaction |
|
| 7 |
Recruiting
|
Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy
| Conditions: |
Nausea; Vomiting |
| Interventions: |
Drug: aprepitant; Drug: Ondansetron |
| Outcome Measures: |
Complete Response rate (no vomiting and no rescue anti-emetic therapy); Complete Response rate; Proportion of patients who did not vomit; No Significant Nausea: The proportion of patients who did not experience any nausea ≥ 3 on 0 - 10 scale; No Nausea: The proportion of patients who did not experience any nausea. Nausea = 0 on 0 - 10 scale; Complete Protection: The proportion of patients who did not vomit, require rescue therapy, or have nausea ≥ 3 on 0 - 10 scale; Total Protection: The proportion of patients who did not vomit, require rescue therapy, or have any nausea (Nausea = 0 on 0 - 10 scale).; Vomiting frequency: The frequency of vomiting (# episodes per week) in patients who did vomit at least once.; Nausea frequency: The frequency of nausea (Nausea > 0 in a given week/ number of weeks during overall period of radiation treatment); Significant Nausea frequency: The frequency of significant nausea (Nausea ≥ 3 in a given week/ number of weeks during overall period of radiation treatment); Frequency of rescue medication use: The number of days in which rescue medication was taken / number of days of radiotherapy; Time to Failure: The time period in days from the start of radiation until the first vomiting episode or use of rescue medication for all patients and for the subset of patients who do not have a Complete Response.; All adverse events that occur during radiation treatment with assessment of severity (CTC v.3) and relationship to study drug. |
|
| 8 |
Unknown †
|
B6 Treatment for Nausea and Vomiting in Pregnancy
| Condition: |
Nausea and Vomiting Complain in Early Pregnancy |
| Intervention: |
Drug: vitamin B6 |
| Outcome Measures: |
Nausea and vomiting score; Vitamin B6 concentration in nausea and vomiting of pregnancy |
|
| 9 |
Not yet recruiting
|
Do Pharyngeal Packs During Orthognathic Surgery Reduce Postoperative Nausea and Vomiting
| Conditions: |
Nausea; Vomiting |
| Intervention: |
Device: pharyngeal pack |
| Outcome Measures: |
the incidence and severity of any nausea, emetic episodes (retching or vomiting), or both (i.e., postoperative nausea and vomiting) during the first 24 postoperative hours.; The incidence and severity of throat pain; the incidence of oral mucosal injury; satisfactory scores of patients |
|
| 10 |
Recruiting
|
Efficacy Study of Ginger (Zingiber Officinale) Extract to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy
| Conditions: |
Cancer; Nausea; Vomiting |
| Intervention: |
Dietary Supplement: Standardized Ginger extract |
| Outcome Measures: |
To evaluate the efficacy of Ginger in protecting patients from delayed nausea (incidence of no delayed nausea and non-significant delayed nausea); Protection from delayed vomiting (number of emetic episodes in delayed phase); Use of antiemetic rescue medication.; Overall fatigue assessment (BFI questionnaire) |
|
| 11 |
Recruiting
|
Nausea and Vomiting in Children Receiving Chemotherapeautic Monotherapy
| Condition: |
Acute Leukemia |
| Intervention: |
|
| Outcome Measures: |
Acute Chemotherapy-Induced Nausea and Vomiting; Anticipatory Chemotherapy-Induced Nausea and Vomiting; Delayed Chemotherapy-Induced Nausea and Vomiting |
|
| 12 |
Recruiting
|
Alternative Approaches for Nausea Control
| Condition: |
Nausea |
| Interventions: |
Device: Acupressure bands; Other: Version 1 handout; Behavioral: Version 1 MP3; Other: Version 2 handout; Behavioral: Version 2 MP3 |
| Outcome Measure: |
patient report nausea diary |
|
| 13 |
Unknown †
|
Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries
| Conditions: |
Nausea; Vomiting |
| Interventions: |
Drug: Dexamethasone; Drug: Aprepitant; Drug: Placebo Dexamethasone |
| Outcome Measures: |
the incidences of nausea, vomiting, need for rescue medication; incidences of unplanned hospital admission; duration of PACU stay |
|
| 14 |
Unknown †
|
Does Thiamine Help Vomiting and Nausea in Pregnancy?
| Condition: |
Hyperemesis Gravidarum |
| Intervention: |
Drug: thiamine & promethazine |
| Outcome Measure: |
the improvement in nausea and/or vomiting after treatment |
|
| 15 |
Recruiting
|
Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy
| Condition: |
Chemotherapy Induced Nausea and Vomiting |
| Interventions: |
Drug: Olanzapine; Drug: Aprepitant |
| Outcome Measures: |
Feasibility of recruitment and data collection.; Complete Response in Overall Phase; Complete Response in Acute Phase; Complete Response in Delayed Phase; Good control of nausea |
|
| 16 |
Recruiting
|
Does Acupressure Help Reduce Nausea and Vomiting in Palliative Care Patients? Formal Study
| Conditions: |
Nausea; Vomiting |
| Interventions: |
Device: Acupressure Wrist Bands (Sea-Bands); Device: Placebo wristbands |
| Outcome Measures: |
Number of PRN Doses of anti-emetics needed; Visual Analogue Scale of nausea; duration of perceived nausea; number of vomits per 24 hours; volume of vomit per 24 hours; adverse effects of acupressure; measure of whether the patient felt the intervention helped. |
|
| 17 |
Recruiting
|
Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
| Condition: |
Emesis |
| Interventions: |
Drug: Dexamethasone, Ondansetron, Aprepitant; Other: Arm A: Standard Anti-emetic regimen |
| Outcome Measures: |
Incidence of change in acute emesis (nausea and/or vomiting) in both study arms; Incidence of change in the delayed emesis (nausea and/or vomiting) in both study arms |
|
| 18 |
Recruiting
|
A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225 AM1) (KMEC)
| Conditions: |
Nausea; Vomiting |
| Interventions: |
Drug: Aprepitant; Drug: Aprepitant Placebo; Drug: Ondansetron; Drug: Dexamethasone; Drug: Ondansetron Placebo; Drug: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride). |
| Outcome Measures: |
The Proportion of Participants with Overall No Vomiting for the Overall Stage; Number of Participants with a Complete Response - Overall, Acute, and Delayed; Time to First Vomiting Event Overall; Number of Participants with No Vomiting and No Significant Nausea; Number of Participants with No Impact on Daily Life - Overall; Number of Participants with No Use of a Rescue Therapy - Overall, Acute, and Delayed; Number of Participants with One or More Clinical Adverse Events; No Vomiting - Acute and Delayed |
|
| 19 |
Unknown †
|
Postoperative Nausea/Vomiting and Acupressure
| Condition: |
Postoperative Nausea |
| Intervention: |
Procedure: Acupressure wrist band |
| Outcome Measures: |
Effectiveness of acupressure for postoperative nausea in terms of less use of antiemetic drugs; Reduction in use of antiemetic medication as a consequence of the introduction of acupressure wristband |
|
| 20 |
Recruiting
|
Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
| Condition: |
Gastroparesis |
| Interventions: |
Drug: Aprepitant; Drug: Placebo |
| Outcome Measures: |
Primary Outcome Measure; Gastrointestinal symptoms; Physiology |
|
